Skip to main content
Erschienen in: World Journal of Urology 5/2007

01.10.2007 | Original Article

Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits

verfasst von: Zhou-Jun Shen, Yi Wang, Guo-Qing Ding, Chun-Wu Pan, Rong-Ming Zheng

Erschienen in: World Journal of Urology | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

To clarify whether intravesical usage of fibrin clot stabilizer epsilon-aminocaproic acid (EACA) or p-aminomethyl benzoic acid (PAMBA) and different injuries enhance fibronectin (FN)-mediated bacillus Calmette-Guérin (BCG) attachment to bladder wall. Thirty New Zealand male white rabbits were randomly divided into five groups and the bladder wall of each rabbit was injured by electrocautery, cryocautery or knife cutting on left lateral wall, right lateral wall and posterior wall in different groups, respectively. Different drug was instilled into the bladder: Group A: pure PBS; B: PBS and radiolabeled BCG (3H-BCG); C: EACA and 3H-BCG; D: PAMBA and 3H-BCG; E: heparin and 3H-BCG. After instillation, each injured and non-injured bladder wall were surgically harvested and digested. The quantity of BCG attachment was detected by liquid scintillation counter (scintillation times per min, STPM). Quantity of BCG attachment to injured bladder wall was significantly (P < 0.01) greater than that of non-injured one, no matter which injury was performed. The BCG attachment to bladder wall in Group C or Group D was significantly (P < 0.05) greater than that of Group B. The quantity of BCG attachment to bladder of Group E was significantly (P < 0.05) less than that of Group B, C and D, respectively. Intravesical instillation of fibrin clot stabilizer (PAMBA, EACA) enhances FN-mediated BCG attachment to bladder wall while heparin inhibits this process. Injuries; e.g., cutting, cryocautery or electrocautery of bladder wall can significantly increase BCG attachment to the bladder wall.
Literatur
1.
Zurück zum Zitat Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183PubMed Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183PubMed
2.
Zurück zum Zitat Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR (1985) Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 25:119–123PubMedCrossRef Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR (1985) Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 25:119–123PubMedCrossRef
3.
Zurück zum Zitat Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95PubMedCrossRef Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95PubMedCrossRef
4.
Zurück zum Zitat Syvester RJ, van der Meijden A.P, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRef Syvester RJ, van der Meijden A.P, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRef
5.
Zurück zum Zitat Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139:410–414PubMed Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139:410–414PubMed
6.
Zurück zum Zitat Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL (1999) Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 274:4521–4526PubMedCrossRef Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL (1999) Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 274:4521–4526PubMedCrossRef
7.
Zurück zum Zitat Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62–67PubMedCrossRef Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62–67PubMedCrossRef
8.
Zurück zum Zitat Böhle A, Brandau S (2003) Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964–969PubMedCrossRef Böhle A, Brandau S (2003) Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964–969PubMedCrossRef
9.
Zurück zum Zitat Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648–661PubMed Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648–661PubMed
10.
Zurück zum Zitat Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144:1362–1364PubMed Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144:1362–1364PubMed
11.
Zurück zum Zitat Witjes JA, vd Meijden AP, Doesburg W, Debruyne FM (1993) Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette-Guerin in the treatment of superficial bladder cancer. Eur Urol 23:366–370PubMed Witjes JA, vd Meijden AP, Doesburg W, Debruyne FM (1993) Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette-Guerin in the treatment of superficial bladder cancer. Eur Urol 23:366–370PubMed
12.
Zurück zum Zitat Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726–3732PubMed Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726–3732PubMed
13.
Zurück zum Zitat Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124:38–40PubMed Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124:38–40PubMed
14.
Zurück zum Zitat Witjes JA (1997) Current recommendations for the management of bladder cancer. Drug therapy. Drugs 53:404–414PubMedCrossRef Witjes JA (1997) Current recommendations for the management of bladder cancer. Drug therapy. Drugs 53:404–414PubMedCrossRef
15.
Zurück zum Zitat Lerner SP, Tangen CM, Suchatew H, Wood D, Crawford ED (2007) Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 177:1727–1731PubMedCrossRef Lerner SP, Tangen CM, Suchatew H, Wood D, Crawford ED (2007) Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 177:1727–1731PubMedCrossRef
16.
Zurück zum Zitat Davies M, Sabbadini E (1982) Mechanisms of BCG action. I. The induction of nonspecific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses. Cancer Immunol Immunother 14:46–53PubMedCrossRef Davies M, Sabbadini E (1982) Mechanisms of BCG action. I. The induction of nonspecific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses. Cancer Immunol Immunother 14:46–53PubMedCrossRef
17.
Zurück zum Zitat Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155–158PubMed Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155–158PubMed
18.
Zurück zum Zitat Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274PubMed Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274PubMed
19.
Zurück zum Zitat Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 310:325–334PubMed Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 310:325–334PubMed
20.
Zurück zum Zitat Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(Suppl):33–36PubMedCrossRef Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(Suppl):33–36PubMedCrossRef
21.
Zurück zum Zitat Patard JJ, Chopin D, Boccon-Gibod L (1993) Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 11:165–168PubMedCrossRef Patard JJ, Chopin D, Boccon-Gibod L (1993) Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 11:165–168PubMedCrossRef
22.
Zurück zum Zitat Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970–974PubMed Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970–974PubMed
23.
Zurück zum Zitat Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 135:268–271PubMed Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 135:268–271PubMed
24.
Zurück zum Zitat Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacillus Calmett-Guerin by bladder tumor cells. J Urol 145:1316–1324PubMed Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacillus Calmett-Guerin by bladder tumor cells. J Urol 145:1316–1324PubMed
25.
Zurück zum Zitat Bevers RF, Kurth KH, Schamhart DH (2004) Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 91:607–612PubMed Bevers RF, Kurth KH, Schamhart DH (2004) Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 91:607–612PubMed
26.
Zurück zum Zitat Peake P, Gooley A, Britton WJ (1993) Mechanism of interaction of the 85B secreted protein of Mycobacterium bovis with fibronectin. Infect Immun 61:4828–4834PubMed Peake P, Gooley A, Britton WJ (1993) Mechanism of interaction of the 85B secreted protein of Mycobacterium bovis with fibronectin. Infect Immun 61:4828–4834PubMed
27.
Zurück zum Zitat Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47:1762–1766PubMed Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47:1762–1766PubMed
28.
Zurück zum Zitat Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27–30PubMed Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27–30PubMed
29.
Zurück zum Zitat Badalament RA, Franklin GL, Page CM, Dasani BM, Wientjes MG, Drago JR (1992) Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer. J Urol 147:482–485PubMed Badalament RA, Franklin GL, Page CM, Dasani BM, Wientjes MG, Drago JR (1992) Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer. J Urol 147:482–485PubMed
30.
Zurück zum Zitat Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83–88PubMedCrossRef Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83–88PubMedCrossRef
31.
Zurück zum Zitat Martin DE, Reece MC, Maher JE, Reese AC (1988) Tissue debris at the injury site is coated by plasma fibronectin and subsequently removed by tissue macrophages. Arch Dermatol 124:226–229PubMedCrossRef Martin DE, Reece MC, Maher JE, Reese AC (1988) Tissue debris at the injury site is coated by plasma fibronectin and subsequently removed by tissue macrophages. Arch Dermatol 124:226–229PubMedCrossRef
32.
Zurück zum Zitat Cheng CY, Martin DE, Leggett CG, Reece MC, Reese AC (1988) Fibronectin enhances healing of excised wounds in rats. Arch Dermatol 124:221–225PubMedCrossRef Cheng CY, Martin DE, Leggett CG, Reece MC, Reese AC (1988) Fibronectin enhances healing of excised wounds in rats. Arch Dermatol 124:221–225PubMedCrossRef
33.
Zurück zum Zitat Grinnell F, Billingham RE, Burgess L (1981) Distribution of fibronetin during wound healing in vivo. J Invest Dermatol 76:181–189PubMedCrossRef Grinnell F, Billingham RE, Burgess L (1981) Distribution of fibronetin during wound healing in vivo. J Invest Dermatol 76:181–189PubMedCrossRef
34.
Zurück zum Zitat Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 144:1362–1364PubMed Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 144:1362–1364PubMed
Metadaten
Titel
Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits
verfasst von
Zhou-Jun Shen
Yi Wang
Guo-Qing Ding
Chun-Wu Pan
Rong-Ming Zheng
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 5/2007
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-007-0198-z

Weitere Artikel der Ausgabe 5/2007

World Journal of Urology 5/2007 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.